levofloxacin has been researched along with Anthrax in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Bower, WA; Bulitta, JB; Chatham-Stephens, K; Cook, R; Hendricks, K; Kennedy, JL; Mongkolrattanothai, T; Negron, ME; Person, MK; Shin, E; Yu, P | 1 |
| Crumrine, M; Hewitt, JA; Slay, RM | 1 |
| Alameh, S; Amali-Adekwu, E; Bartolo, G; Beasley, DWC; Bradley, KA; Cheng, LW; Chugunova, M; Cote, CK; Demons, ST; Derbedrossian, A; Fetterer, DP; Halasahoris, SA; Hartmann, S; Ho, CC; Kao, CY; Klimko, CP; Lawrence, WS; Levitin, A; Martchenko Shilman, M; McComb, R; Miller, LL; Peel, JE; Peterson, JW; Shoe, JL; Sivasubramani, SK; Tran, JK; West, J; Zilbermintz, L | 1 |
| Carpenter, S; Henning, LN; Serbina, NV; Stark, GV | 1 |
| Xie, H; Yuan, HL; Zhang, W; Zheng, YY | 1 |
| Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Comer, J; Kammanadiminti, S; Kodihalli, S; Meister, G; Patnaikuni, RK; Sinclair, C | 1 |
| Bolmer, S; Buccellato, M; Corey, A; Meister, G; Migone, TS; Vasconcelos, D; Zhong, J | 1 |
| Head, BM; Meyers, AF; Rubinstein, E | 1 |
| Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW | 1 |
| Dyer, DN; Hatkin, JM; Orr, SA; Pitt, ML; Yee, SB | 1 |
| Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED | 1 |
| Bolmer, S; Chen, C; Corey, A; Fiscella, M; Meister, G; Migone, TS; Ward, C | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M | 1 |
| Doganay, M; Esel, D; Sumerkan, B | 1 |
| Basset, J; Bush, K; Byrne, WR; Deziel, MR; Drusano, GL; Heine, H; Kao, M; Kelly, M; Louie, A; Miller, L | 1 |
| Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW | 1 |
2 review(s) available for levofloxacin and Anthrax
| Article | Year |
|---|---|
Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; beta-Lactams; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Doxycycline; Glycopeptides; Humans; Levofloxacin; Lipopeptides; Models, Animal; Tetracyclines; United States | 2022 |
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence | 2016 |
1 trial(s) available for levofloxacin and Anthrax
| Article | Year |
|---|---|
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Topics: Adolescent; Aging; Anthrax; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Body Weight; Child; Child, Preschool; Chromatography, High Pressure Liquid; Double-Blind Method; Female; Humans; Infant; Inhalation Exposure; Injections, Intravenous; Kidney Function Tests; Levofloxacin; Male; Ofloxacin; Spores, Bacterial; Tablets | 2010 |
14 other study(ies) available for levofloxacin and Anthrax
| Article | Year |
|---|---|
Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Azithromycin; Bacillus anthracis; Clarithromycin; Disease Models, Animal; Levofloxacin; Macaca fascicularis; Respiratory Tract Infections | 2022 |
Topics: Amodiaquine; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Levofloxacin; Mice; Rabbits; Systematic Reviews as Topic | 2021 |
Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Drug Therapy, Combination; Female; Immunization, Passive; Immunoglobulin G; Immunologic Memory; Levofloxacin; Male; Rabbits; Random Allocation; Respiratory Tract Infections; Spores, Bacterial; Survival Analysis | 2018 |
Two cases of human cutaneous anthrax with massive tissue damage, severe edema, and slight injury to the liver.
Topics: Adult; Anthrax; Biopsy, Needle; Blister; Drug Therapy, Combination; Edema; Humans; Immunohistochemistry; Levofloxacin; Liver; Male; Methylprednisolone; Middle Aged; Penicillin G; Prognosis; Risk Assessment; Skin Diseases, Bacterial; Soft Tissue Injuries; Treatment Outcome; Upper Extremity | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Ciprofloxacin; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Combinations; Imipenem; Levofloxacin; Linezolid; Meningitis, Bacterial; Meropenem; Rabbits; Treatment Failure | 2018 |
Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacteremia; Disease Models, Animal; Drug Therapy, Combination; Female; Immunoglobulins, Intravenous; Levofloxacin; Male; Rabbits; Respiratory Tract Infections; Toxemia; Treatment Outcome | 2014 |
Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Levofloxacin; Male; Rabbits; Respiratory Tract Infections | 2015 |
Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacteremia; Biomarkers; Female; Levofloxacin; Male; Ofloxacin; Rabbits; Spores, Bacterial; Time Factors | 2010 |
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacterial; Bacterial Toxins; Disease Models, Animal; Drug Therapy, Combination; Humans; Immunoglobulin G; Levofloxacin; Ofloxacin; Post-Exposure Prophylaxis; Rabbits; Recombinant Proteins; Respiratory Tract Infections; Survival Analysis; Treatment Outcome; Vaccination | 2012 |
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Topics: Adjuvants, Immunologic; Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Disease Models, Animal; Female; Kinetics; Levofloxacin; Male; Ofloxacin; Rabbits; Spores, Bacterial; Survival Analysis | 2013 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Penicillins; Thienamycins | 2002 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin G; Penicillins; Turkey | 2003 |
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Topics: Animals; Anthrax; Anti-Infective Agents; Bacillus anthracis; Humans; Levofloxacin; Macaca mulatta; Mice; Ofloxacin; Preventive Medicine | 2005 |
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Area Under Curve; Bacillus anthracis; Computer Simulation; Dose-Response Relationship, Drug; Drug Compounding; Female; Humans; Inhalation Exposure; Levofloxacin; Macaca mulatta; Male; Microbial Sensitivity Tests; Ofloxacin; Spores, Bacterial | 2006 |